Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 91Myeloid 67Lymphoid 67Plasma cell 32Classical hematology 27Sarcoma 21Dermatologic 14CNS 7Genitourinary 4Breast 4Other neoplasm 3Gynecologic 2Thoracic 1Gastrointestinal 1

Conditions

Fibrolamellar hepatocellular carcinoma 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Antilymphocyte Serum × Gastrointestinal × Clear all
NCT02702960 2018-06-15

Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Withdrawn
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡